# A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

> **NCT05064436** · PHASE1 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 10 (actual)

## Conditions studied

- Multiple Sclerosis (MS)

## Interventions

- **DRUG:** 11C-BMS-986196

## Key facts

- **NCT ID:** NCT05064436
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-10
- **Primary completion:** 2023-12-18
- **Final completion:** 2023-12-18
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05064436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05064436, "A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05064436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*